SELLAS reports Q1 2026 financial results and corporate update
Cash position $107.1M, REGAL trial at 78 events, SLS009 Phase 2 dosing ongoing.
See the latest news and media coverage for SELLAS. We track all announcements, press releases, and industry mentions in real time, all in one place.
Late-stage clinical biopharmaceutical company
sellaslifesciences.comLast updated
In short: SELLAS Life Sciences progressed its AML pipeline, nearing a pivotal trial readout for GPS while reporting first-quarter 2026 financial results.
Cash position $107.1M, REGAL trial at 78 events, SLS009 Phase 2 dosing ongoing.
Cash position $71.8M; net loss $26.9M; progress in GPS and SLS009 trials.
The randomized Phase 2 study will enroll 80 patients unlikely to benefit from standard therapy.
The collaboration aims to enable broader U.S. and European patient enrollment for SLS009 in frontline AML.
Sellas Life Sciences Group Inc. (NASDAQ:SLS) is one of the 9 Stocks Winning by Double Digits. Sellas...
Investors approved an amendment to Sellas' equity incentive plan, expanding the share pool by 20...
Traders expect the HKIAC tribunal to formally close proceedings, with a final ruling potentially due...
In recent days, SELLAS Life Sciences Group drew attention as its CEO highlighted real-world data and...
Track SELLAS and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to SELLAS and other trending companies.